CHARLESTON, S.C.--(BUSINESS WIRE)--
Aeterna Zentaris Inc. (AEZS) (AEZS.TO) (the “Company”) will announce its third quarter 2017 financial and operating results after market close on Wednesday, November 8, 2017. The Company will host a conference call to discuss these results on Thursday, November 9, 2017 at 8:30 a.m. Eastern Time.
Participants may access the conference call using the following numbers:
- Toll-Free: 877-407-8029, Confirmation #13672701
- Toll: 201-689-8029, Confirmation #13672701
A replay of the conference call will also be available on the Company’s website for a period of 30 days.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel pharmaceutical therapies. We are engaged in drug development activities and in the promotion of products for others. We recently resubmitted an NDA to the FDA seeking approval of MacrilenTM, an internally developed compound. The focus of our business development efforts is the acquisition of licenses to products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in non-U.S. territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.